Disease ⇒ Osteoporosis {40000118}
| Type: | Disease |
|---|---|
| Parent: | [ ] |
| Definition: | Osteoporosis |
| Initialisation date: | 2020-09-06 |
|---|---|
| Other Terms: | [ ] |
| MedDra ID: | 10031282 |
|---|---|
| MedDra Level: | pt |
| ICD: | [ ] |
| Category: | Musculoskeletal, Rheumatology |
| Zone: | [ ] |
| Mechanism: | [ ] |
Notes:
- Warmth enhances bacterial polyamine biosynthesis, resulting in higher total polyamine levels in vivo. Spermine and spermidine supplementation increases bone strength, while inhibiting polyamine biosynthesis in vivo limits the beneficial warmth effects on the bone. (1)
Shared Reference Notes
- [1.1]
- Gut microbiome is a communicable regulator of bone structure and turnover in mice. - Acquisition of a specific bacterial strain, segmented filamentous bacteria (SFB), a gut microbe that induces intestinal Th17 cell expansion, was sufficient to negatively impact skeletal maturation. - [1.2]
- #Antibiotic Therapy with Broad-spectrum beta-lactam, amoxicillin > greater abundance of #oxalate-degradation genes present in the gut microbiome post-antibiotic treatment > A reduction in levels of #oxalate, a major calcium-binding anion in the intestinal lumen > facilitate a greater availability and absorption of calcium from the intestines > enhancing bone mineralisation > increase in Bone Mineral Density - [1.3] [#Limosilactobacillus (Lactobacillus) reuteri] [#Probiotic]
- L. reuteri > Could reduce bone loss associated with estrogen deficiency in an ovariectomized (Ovx) mouse menopausal model. - Osteoclast bone resorption markers and activators (Trap5 and RANKL) as well as osteoclastogenesis are significantly decreased in L. reuteri-treated mice. - L. reuteri treatment may be a straightforward and cost-effective approach to reduce post-menopausal bone loss. - [1.4]
- A peptide from the von Willebrand factor type A domain protein (vWFA) was the most potent activator of Ro60-reactive T cells.
References Notes
[ ]